Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Dmitriy Zamarin, Kunle Odunsi, Emese Zsiros, Brian M. Slomovitz, Agustin Pimentel, Linda R. Duska, Matthew Reilley, John J. Nemunaitis, Danae M. Hamouda, Hitendra Patel, Neil Howard Segal, Giulio Pesci, Aliya Holland, Lisa Shohara, Paul Otto Schwarzenberger, Toni Ricciardi, Mary J. Macri, Aileen Ryan, Magnus Erik Jaderberg, Ralph Rudolph Venhaus
Institutions: Memorial Sloan Kettering Cancer Center, University of Chicago, Roswell Park Comprehensive Cancer Center, Mount Sinai Medical Center, University of Miami, Sylvester Comprehensive Cancer Center, University of Virginia, University of Toledo Medical Center, University of California San Diego, Ludwig Cancer Research, Targovax (Norway)
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4286294077